About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

Platinum

  • Basics

INFORM Study
This is a study for newly-diagnosed breast cancer patients with BRCA mutations. The study is evaluating whether the chemotherapy drug cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients.

Treatment for Triple-Negative Breast Cancer
2010 FORCE webinar presented by Dr. Melinda Telli of Stanford, providing updates on research specific to triple-negative breast cancer.


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org